Antibody data
- Antibody Data
- Antigen structure
- References [4]
- Comments [0]
- Validations
- Western blot [2]
- Immunohistochemistry [1]
Submit
Validation data
Reference
Comment
Report error
- Product number
- ABIN2839126 - Provider product page
- Provider
- antibodies-online
- Product name
- anti-CD90 (THY1) (AA 36-65), (N-Term) antibody
- Antibody type
- Polyclonal
- Description
- This antibody is prepared by Saturated Ammonium Sulfate (SAS) precipitation followed by dialysis against PBS.
- Reactivity
- Human
- Host
- Rabbit
- Epitope
- AA 36-65, N-Term
- Antibody clone number
- RB03970
- Vial size
- 80 μL
- Storage
- Maintain refrigerated at 2-8°C for up to 6 months. For long term storage store at -20°C in small aliquots to prevent freeze-thaw cycles.
Submitted references Quantitative Analysis of Differential Proteome Expression in Bladder Cancer vs. Normal Bladder Cells Using SILAC Method.
High expression levels of putative hepatic stem/progenitor cell biomarkers related to tumour angiogenesis and poor prognosis of hepatocellular carcinoma.
Thy-1 expression in human fibroblast subsets defines myofibroblastic or lipofibroblastic phenotypes.
THY1 expression is associated with tumor suppression of human ovarian cancer.
Yang G, Xu Z, Lu W, Li X, Sun C, Guo J, Xue P, Guan F
PloS one 2015;10(7):e0134727
PloS one 2015;10(7):e0134727
High expression levels of putative hepatic stem/progenitor cell biomarkers related to tumour angiogenesis and poor prognosis of hepatocellular carcinoma.
Yang XR, Xu Y, Yu B, Zhou J, Qiu SJ, Shi GM, Zhang BH, Wu WZ, Shi YH, Wu B, Yang GH, Ji Y, Fan J
Gut 2010 Jul;59(7):953-62
Gut 2010 Jul;59(7):953-62
Thy-1 expression in human fibroblast subsets defines myofibroblastic or lipofibroblastic phenotypes.
Koumas L, Smith TJ, Feldon S, Blumberg N, Phipps RP
The American journal of pathology 2003 Oct;163(4):1291-300
The American journal of pathology 2003 Oct;163(4):1291-300
THY1 expression is associated with tumor suppression of human ovarian cancer.
Abeysinghe HR, Cao Q, Xu J, Pollock S, Veyberman Y, Guckert NL, Keng P, Wang N
Cancer genetics and cytogenetics 2003 Jun;143(2):125-32
Cancer genetics and cytogenetics 2003 Jun;143(2):125-32
No comments: Submit comment
Supportive validation
- Submitted by
- antibodies-online (provider)
- Main image
- Experimental details
- WB
- Submitted by
- antibodies-online (provider)
- Main image
- Experimental details
- WB
Supportive validation
- Submitted by
- antibodies-online (provider)
- Main image
- Experimental details
- IHC